Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Coya Therapeutics, Inc. - Common Stock (NQ:COYA)

4.080 +0.140 (+3.55%)

Streaming Delayed Price Updated: 4:00 PM EDT, Apr 1, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	111,859
Open	4.000
Bid (Size)	4.050 (1,500)
Ask (Size)	4.150 (300)
Prev. Close	3.940
Today's Range	3.990 - 4.190
52wk Range	3.710 - 7.750
Shares Outstanding	9,947,915
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Coya Therapeutics Announces Publication Demonstrating Regulatory T-Cell Dysfunction and Systemic Inflammation in Frontotemporal Dementia, Supporting Mechanistic Rationale for COYA 302 Immune-Restoring Therapy

March 18, 2026

From Coya Therapeutics, Inc.

Via Business Wire

Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2025 Financial Results

March 16, 2026

From Coya Therapeutics, Inc.

Via Business Wire

Performance

YTD	-27.8%	-27.8%
1 Month	-16.9%	-16.9%
3 Month	-26.4%	-26.4%
6 Month	-28.4%	-28.4%
1 Year	-36.9%	-36.9%

More News

Coya Therapeutics to Host Webinar with Leading Medical Experts on Amyotrophic Lateral Sclerosis (ALS) Drug Development, Patient Landscape, and Ongoing Clinical Trial

February 10, 2026

From Coya Therapeutics, Inc.

Via Business Wire

Coya Therapeutics Announces $11.1 Million Private Placement

January 30, 2026

From Coya Therapeutics, Inc.

Via Business Wire

Coya Therapeutics CEO Dr. Arun Swaminathan Issues Letter to Stockholders

January 20, 2026

From Coya Therapeutics, Inc.

Via Business Wire

Coya Therapeutics Announces Results of Investigator-Initiated Study of LD IL-2 and CTLA4-Ig Demonstrating Treg Enhancement and Cognitive Stability in Frontotemporal Dementia Patients

January 08, 2026

From Coya Therapeutics, Inc.

Via Business Wire

Coya Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Frontotemporal Dementia (FTD)

January 05, 2026

From Coya Therapeutics, Inc.

Via Business Wire

Coya Therapeutics Receives Clinical Trial Application (CTA) Acceptance from Health Canada to Proceed with the COYA 302 ALSTARS Trial for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

December 23, 2025

From Coya Therapeutics, Inc.

Via Business Wire

Coya Therapeutics Announces Patients Have Been Dosed in the ALSTARS Trial of COYA 302 for the Treatment of ALS

December 09, 2025

From Coya Therapeutics, Inc.

Via Business Wire

Coya Therapeutics to Participate in Upcoming Investor Relations and Clinical Trials Conferences

November 25, 2025

From Coya Therapeutics, Inc.

Via Business Wire

Coya Therapeutics Reports Third Quarter Financial Results and Provides a Corporate Update

November 12, 2025

From Coya Therapeutics, Inc.

Via Business Wire

Coya Therapeutics Announces That Its Combination LD IL-2/GLP-1 RA Candidate (COYA 303) Demonstrated Potent Systemic and Brain Anti-Inflammatory Efficacy In Vivo

November 04, 2025

From Coya Therapeutics, Inc.

Via Business Wire

Coya Therapeutics Announces Closing of $23.0 Million Upsized Public Offering of Common Stock, Including Full Exercise of Underwriter’s Option to Purchase Additional Shares

October 27, 2025

From Coya Therapeutics, Inc.

Via Business Wire

Get insights into the top gainers and losers of Friday's pre-market session. ↗

October 24, 2025

Via Chartmill

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

October 24, 2025

Via Benzinga

Coya Therapeutics Announces Pricing of $20 Million Upsized Public Offering of Common Stock

October 24, 2025

From Coya Therapeutics, Inc.

Via Business Wire

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

October 23, 2025

Via Benzinga

Coya Therapeutics Announces Proposed Public Offering of Common Stock

October 23, 2025

From Coya Therapeutics, Inc.

Via Business Wire

Coya Therapeutics Congratulates Scientific Advisor Dr. Shimon Sakaguchi for Receiving The Nobel Prize in Physiology or Medicine for Discovery of Regulatory T Cells and Immune Function

October 07, 2025

From Coya Therapeutics, Inc.

Via Business Wire

EXCLUSIVE: Coya Therapeutics Investigational Combination Therapy With GLP-1 Shows Potential For Alzheimer's Disease ↗

September 16, 2025

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

August 25, 2025

Via Benzinga

What's Going On With Coya Therapeutics Stock? ↗

August 25, 2025

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

August 25, 2025

Via Benzinga

Coya Therapeutics Announces Publication of Scientific Research Linking Inflammation and Oxidative Stress to the Progression of Parkinson’s Disease

July 24, 2025

From Coya Therapeutics, Inc.

Via Business Wire

Coya Therapeutics to Participate in the BTIG Virtual Biotechnology Conference July 29 – 30, 2025

July 22, 2025

From Coya Therapeutics, Inc.

Via Business Wire

Frequently Asked Questions

Is Coya Therapeutics, Inc. - Common Stock publicly traded?

Yes, Coya Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Coya Therapeutics, Inc. - Common Stock trade on?

Coya Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Coya Therapeutics, Inc. - Common Stock?

The ticker symbol for Coya Therapeutics, Inc. - Common Stock is COYA on the Nasdaq Stock Market

What is the current price of Coya Therapeutics, Inc. - Common Stock?

The current price of Coya Therapeutics, Inc. - Common Stock is 4.080

When was Coya Therapeutics, Inc. - Common Stock last traded?

The last trade of Coya Therapeutics, Inc. - Common Stock was at 04/01/26 04:00 PM ET

What is the market capitalization of Coya Therapeutics, Inc. - Common Stock?

The market capitalization of Coya Therapeutics, Inc. - Common Stock is 40.59M

How many shares of Coya Therapeutics, Inc. - Common Stock are outstanding?

Coya Therapeutics, Inc. - Common Stock has 41M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.